

Understanding and treating refractory constipation

Gabrio Bassotti, Corrado Blandizzi

Gabrio Bassotti, Gastroenterology and Hepatology Section, Department of Medicine, University of Perugia, 06156 Perugia, Italy

Corrado Blandizzi, Division of Pharmacology and Chemotherapy, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy

Author contributions: Bassotti G ideated the project and wrote the draft; Blandizzi C critically reviewed the manuscript and helped in writing the manuscript; both authors reviewed and approved the final version of the manuscript.

Correspondence to: Gabrio Bassotti, Professor, Gastroenterology and Hepatology Section, Department of Medicine, University of Perugia, Ospedale Santa Maria della Misericordia, Piazzale Menghini 1, 06156 Perugia, Italy. gabassot@tin.it
Telephone: +39-75-5784423 Fax: +39-75-5847570

Received: October 17, 2013 Revised: January 20, 2014

Accepted: February 18, 2014

Published online: May 6, 2014

Abstract

Chronic constipation is a frequently encountered disorder in clinical practice. Most constipated patients benefit from standard medical approaches. However, current therapies may fail in a proportion of patients. These patients deserve better evaluation and thorough investigations before their labeling as refractory to treatment. Indeed, several cases of apparent refractoriness are actually due to misconceptions about constipation, poor basal evaluation (inability to recognize secondary causes of constipation, use of constipating drugs) or inadequate therapeutic regimens. After a careful re-evaluation that takes into account the above factors, a certain percentage of patients can be defined as being actually resistant to first-line medical treatments. These subjects should firstly undergo specific diagnostic examination to ascertain the subtype of constipation. The subsequent therapeutic approach should be then tailored according to their underlying dysfunction. Slow transit patients could benefit from a more robust medical treatment, based on stimulant laxatives (or their combination with osmotic laxatives, particularly over the short-term), enterokinetics (such

as prucalopride) or secretagogues (such as lubiprostone or linaclotide). Patients complaining of obstructed defecation are less likely to show a response to medical treatment and might benefit from biofeedback, when available. When all medical treatments prove to be unsatisfactory, other approaches may be attempted in selected patients (sacral neuromodulation, local injection of botulinum toxin, antegrade continence enemas), although with largely unpredictable outcomes. A further although irreversible step is surgery (subtotal colectomy with ileorectal anastomosis or stapled transanal rectal resection), which may confer some benefit to a few patients with refractoriness to medical treatments.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

Key words: Chronic constipation; Laxatives; Medical treatment; Refractory constipation; Surgical treatment

Core tip: The majority of patients affected by chronic constipation can be managed by conventional therapeutic approaches. However, a subset of constipated patients displays a condition of actual refractoriness to standard medical treatment, even after careful clinical re-evaluation. These patients require more in-depth diagnostic evaluations to ascertain the underlying pathophysiological mechanisms, as well as more intensive, targeted and tailored therapeutic approaches, which may rely on the use of newly released drugs (enterokinetics, enteric secretagogues), rehabilitation (biofeedback), invasive measures (sacral neuromodulation, local injection of botulinum toxin, antegrade continence enemas) and surgical procedures (subtotal colectomy with ileorectal anastomosis or stapled transanal rectal resection).

Bassotti G, Blandizzi C. Understanding and treating refractory constipation. *World J Gastrointest Pharmacol Ther* 2014; 5(2): 77-85 Available from: URL: <http://www.wjgnet.com/2150-5349/full/v5/i2/77.htm> DOI: <http://dx.doi.org/10.4292/wjgpt.v5.i2.77>

INTRODUCTION

Chronic constipation is one of the most frequent complaints faced by physicians during their daily activity^[1] since a relatively large number of subjects in the general population (ranging from about 9% to more than 20%, depending on the geographical area) is or believe to be affected by constipation^[2]. The costs for medical care are high for patients complaining of constipation, from childhood to adulthood^[3]. Constipation is highly prevalent among female subjects^[4] and it has been demonstrated that women with constipation have significantly higher medical care utilization and expenditures compared with women without constipation^[5].

At present, constipated patients can be managed by a variety of medical therapeutic options that yield satisfying results in most cases^[6,7]. However, a subset of constipated patients fails to benefit from conventional (and sometimes even intensive) treatments^[8]. Although these subjects are often regarded as being resistant to therapy, their refractoriness may not be actual in nature but rather results from several factors related to the patient, the physician, or to their false beliefs and misunderstandings, as discussed in detail below. However, after careful re-evaluation, some patients are found to hold a condition of true refractory constipation, which is often a therapeutic challenge and deserves different and more tailored therapeutic approaches, up to demolitive surgical procedures.

The pharmacotherapy of refractory constipation is currently regarded as a challenging area, where the paucity of supportive clinical evidence and the persistence of unmet medical needs demand urgent attention in terms of focused clinical research and consensus by experts. Based on these considerations, the present article intends to review current information on the different approaches to the therapeutic management of refractory constipation, with the primary purpose of fostering the debate on this issue and generating new ideas for future clinical research on the employment of old and new drugs.

GENERAL CONSIDERATIONS

As anticipated above, to date, refractory constipation is suspected when a patient, fulfilling the standard diagnostic criteria for functional constipation^[9] and lacking any alarm feature for organic conditions, fails to improve upon intake of a high-fiber diet and laxatives, usually polyethylene glycol (PEG) or other osmotic agents^[10], the former being superior to lactulose in improving stool frequency, stool consistency and abdominal pain^[11].

When facing a constipated patient complaining of resistance to the above therapeutic approaches, there are several issues which deserve careful consideration before labeling the patient as refractory to standard treatment and going on with further diagnostic evaluations and/or

therapeutic interventions.

Reliability of information and patient compliance

This point could appear tautological in nature but, based on clinical experience, a certain number of patients are labeled as being “refractory” to medical treatment merely because of misunderstandings with the prescribing physician (*i.e.*, poor or altogether complete lack of communication, lack of acceptance of chronicity of the condition, unwillingness to use drugs long-term, scarce understanding of dose regimens, *etc.*) or as a result of misconceptions on the actual nature and relevance of constipation^[12].

Patient expectations

It frequently happens that patients initially classified as refractory to treatment at a more accurate medical interview disclose that they discontinued drug intake after a very few days of therapy owing to the lack of effect onset. In these cases, it is common to find that these patients had not had explained to them that the basic treatment of constipation (*i.e.*, high-fiber diet, PEG or other osmotic agents) may require several days or weeks prior to achieving the effect onset or full effectiveness.

Poor basal evaluation

Patients with suspected refractoriness to medical treatment should be accurately re-evaluated for secondary forms of constipation, with particular regard for those associated with the use of drugs, a condition which can be unraveled only after repeated enquiries, focusing on specific drug classes. This issue is of particular relevance since some forms of drug-induced constipation (*e.g.*, that secondary to the use of opioid analgesics) can be managed by specific therapeutic approaches^[13], whereas other (*e.g.*, that secondary to the use of antidepressants) can influence colonic motility to such a degree of severity^[14,15] that they may require discontinuation of the offending drug or a switch to different drugs. Another sensitive and easy to miss condition, requiring a strong patient-physician relationship owing to the peculiarity of the issue, is a previous history (often only disclosed after several interviews) of physical or sexual abuse, found mainly in patients with symptoms of obstructed defecation (OD)^[16].

Once ascertained that none of the above conditions can be called into play, the patient usually undergoes further diagnostic evaluations in an attempt to highlight specific pathophysiological mechanisms which might drive focused therapeutic interventions^[17]. For this purpose, a further diagnostic step must include the evaluation of intestinal transit time^[18], anorectal manometry^[19] (complemented by the rectal balloon expulsion test^[20]) and defecography^[21]. Upper gastrointestinal (which might limit or preclude surgical procedures)^[22,23] and colonic manometry (possibly with pharmacological testing in patients regarded as eligible for surgery, see below)^[24,25] might also be performed.

These investigations usually allow allocation of con-

stipated patients into two major subgroups, comprising those with slow transit constipation (STC) and those with OD, even although it is not uncommon that some patients display both features at the same time^[6].

The hallmark of patients with STC is delayed colonic transit, a condition which can be documented by a delayed distribution of radiopaque markers (or radionuclides) throughout the visceral lumen^[26] and is characterized by a severe impairment of colonic motor activity that, in some instances, can be almost absent or progress up to a true picture of colonic inertia^[27].

In patients with OD, the main pathophysiological features are basically related to rectoanal dysfunction, including the inability to relax or the paradoxical contraction of the pelvic floor while attempting to defecate^[28], the lack of rectal motor activity^[29], and an abnormal rectal sensitivity^[30], although anatomical abnormalities (particularly rectocele and rectal intussusceptions) can also play a role in this setting^[31].

A condition of apparent refractoriness to drug therapy in these two subgroups of patients may thus be underpinned by different pathophysiological grounds that may deserve different medical and/or non-medical (surgical, behavioral) approaches.

THERAPEUTIC MANAGEMENT OF REFRACTORY PATIENTS: PHARMACOLOGICAL APPROACH

In patients with true unresponsiveness to first-line osmotic laxatives, a combination approach can be used, introducing stimulant laxatives such as bisacodyl and sodium picosulfate. These agents are able to elicit bowel propulsion^[32], as well as to exert antiabsorptive and secretory effects on the enteric mucosa, and appear to be quite safe even in the long-term^[6]. Initially, these drugs should be employed as rescue agents when patients do not defecate after two-three days while using osmotic agents^[33], although patients should be encouraged to persist for longer periods on osmotic laxatives before adding a stimulant agent. Of note, controlled clinical studies on stimulant laxatives have been published only in recent years and they have documented both the effectiveness of these agents and their favorable impact on disease-related quality of life, even in the medium-term^[34-36]. Moreover, the supposed damaging actions of stimulant laxatives on enteric neural structures have not been confirmed by means of modern techniques^[37]. Nevertheless, data on the long-term use of stimulant laxatives, either alone or in combination with osmotic laxatives, are lacking. Moreover, even laxative combinations may not be sufficient to achieve a satisfactory and steady resolution of constipation. Therefore, pharmacological research in this area has moved towards drugs that might be able to increase or restore the propulsive activity of the large bowel, in both the short- and long-term.

In this context, a promising drug, tegaserod, endowed with enteric prokinetic effects resulting from its

partial agonistic activity on 5-HT₄ serotonin receptors, was withdrawn from the drug market due to concerns about possible adverse cardiovascular effects^[38] and the research in this area shifted towards the development of effective drugs devoid of cardiovascular toxicity. Along this line, prucalopride, a thoroughly studied prokinetic drug with particular regard for its cardiovascular safety, has been recently introduced in Europe for treatment of constipated women not responding to conventional first-line regimens^[39]. This compound is a potent and selective 5-HT₄ receptor full agonist endowed with enterokinetic properties^[40], able to accelerate the gastrointestinal and colonic transit in constipated patients without abnormal rectal evacuatory dysfunction^[41], probably as a result of an increase of high-amplitude propulsive contractions^[42]. Controlled studies in patients (mostly women) unresponsive to standard medical regimens have shown that this drug (at the dose of 2 mg/d in adults and 1 mg/d in the elderly) can be effective in relieving constipation both in the short- and long-term^[43-47], even in patients from non-Western countries^[48]. Of note, although in clinical trials prucalopride appeared to be less effective in patients with symptoms of OD^[49], a recent study conducted under real-life conditions showed its efficacy even in this setting (with similar percentages to those reported in clinical trials)^[50], suggesting that this drug can be regarded as an additional therapeutic tool for refractory patients to provide them with an additional chance to manage their complaints^[51]. Moreover, a recent report showing that prucalopride can be as effective as PEG in resolving constipation^[52] allows the hypothesis that these two drugs, known to act in different ways and not burdened by serious adverse effects, might be (as already observed empirically in our routine clinical experience) combined advantageously to achieve positive therapeutic results in refractory patients.

With the recent introduction of enteric secretagogues, other therapeutic tools have been made available. The first drug of this class to be approved (currently in USA, but not in Europe) was lubiprostone, a fatty acid structurally related to prostaglandin E₁ which acts primarily by activating apical ClC-2 chloride channels in enteric epithelial cells^[53]. This compound has been shown to improve constipation (at a dose of 24 µg twice a day)^[54-57], even in the long-term^[58]. More recently, linaclotide, a guanylate cyclase-C agonist, has been approved in some European countries for treatment of patients with chronic constipation^[59]. The activation of guanylate cyclase-C by linaclotide results in an increase in both intracellular and extracellular levels of cyclic guanosine monophosphate, which then stimulates chloride and bicarbonate secretion from enteric epithelial cells into the bowel lumen, leading to an increment of luminal fluids and transit acceleration^[59]. This drug (at a dose of 145 µg once daily) has been found to be effective in the short-term for treatment of chronic constipation^[60-62], as also stressed in a recent meta-analysis^[63]. Since both lubiprostone and linaclotide display different mechanisms of action compared to laxatives or prokinetics, it is likely that their combination with other drugs (for instance, stimulant laxatives

or prucalopride) might help to improve symptoms in patients with refractory constipation. This represents an important medical need which should be addressed by means of specific clinical trials exploring the suitability of drug combinations.

Other pharmacological options

There is evidence from both controlled and non-controlled clinical trials that colchicine, an old drug still available for the treatment of gout at the dose of 0.6 mg three times per day, can be effective (at least in the short-term) to manage constipated patients, including those refractory to other therapeutic approaches^[64-66]. Unfortunately, colchicine has a narrow therapeutic index which is associated with underestimated toxicity and frequent and serious adverse effects^[67] that confines its use to extremely selected cases in whom no other options, including surgery (see below), are viable.

The inhibitor of ileal bile acid transporter A3309, after having displayed some benefit in a small pilot clinical study^[68], was also shown to be effective in accelerating colonic transit^[69] and in treating constipated patients at a daily dose of 10 mg in phase 2 studies^[70]. Based on these preliminary experiences, further studies are clearly needed to confirm both the efficacy and safety profile of A3309 in chronic refractory constipation.

An interesting small phase 2 study has suggested that the cholinesterase inhibitor pyridostigmine (60-120 mg three times per day), available in the pharmaceutical market for many years, is able to accelerate colonic transit and improve symptoms in constipated patients with type 2 diabetes mellitus^[71]. Since this drug is widely available and (in contrast to newer drugs) relatively inexpensive, further studies are warranted to explore its suitability in idiopathic chronic constipation.

THERAPEUTIC MANAGEMENT OF REFRACTORY PATIENTS: OTHER THERAPEUTIC APPROACHES

In patients with primary defects involving defecatory disorders, particularly OD, currently available medical regimens (although often used as first-line approaches) can be disappointing. Indeed, these patients have been shown to benefit more from behavioral and retraining techniques^[72-74], particularly biofeedback^[75,76], than drug therapies. Although the efficacy of biofeedback has been advocated for a long time^[77], controlled trials have only in recent years shown its efficacy in the treatment of constipation associated with OD^[78-83], even in elderly patients^[84], although some authors have reported a limited efficacy in the long-term when compared to botulinum toxin^[85]. Interestingly, there seems to be no difference among the various available biofeedback techniques in terms of efficacy^[86]. However, notwithstanding the good results achieved in the treatment of OD with better therapeutic performances than those of laxatives, biofeedback still appears to have a quite limited role in routine clinical

practice, likely because of the scarce appreciation of the benefits achievable with pelvic floor retraining and the limited availability of experienced trainers. Electrogalvanic stimulation, although effective in individual OD patients^[87,88], has not been formally studied in controlled trials.

In selected OD patients, local injections of botulinum toxin have been attempted with a certain success, although the evidence remains very scarce and is based on uncontrolled studies^[89,90]. Owing to such limitations, this approach cannot be proposed as a standard treatment but should be restricted to patients unresponsive to any other available medical therapy before considering a surgical approach or be employed only for research purposes.

When considering surgical strategies, one should always keep in mind that surgery is usually an irreversible option and that the surgical approach *per se* may introduce or add further damage to an already malfunctioning intestine. Thus, the ideal surgical approach should be aimed at achieving the best results with the minimum of invasiveness. Accordingly, the following paragraphs address the surgical options currently employed for the management of refractory constipated patients.

There is limited experience in adults with antegrade continence enemas (the so-called Malone procedure), which is a relatively invasive surgical procedure proven to be quite successful in children^[91] that seems to work in approximately 50% of patients undergoing this procedure^[92,93]. The theoretical advantage associated with this technique is that, should the colonic function be recovered, it would be possible to restore the intestinal continuity without a need for resections. However, in current practice this goal can be rarely, if ever, pursued.

A more draconian approach, which can be considered in refractory STC patients when pelvic floor dysfunction and relevant upper gastrointestinal motor abnormalities have been excluded^[22,94,95], is subtotal colectomy with ileorectal anastomosis^[96]. Provided that the above criteria are fulfilled, this technique offers interesting long-term benefits to patients^[97]. Conversely, the results are poorer when such criteria are not duly fulfilled^[98]. Of course, postoperative complications (*i.e.*, small bowel obstruction, wound infection, anastomotic leakage) may occur as with any surgical intervention, the most frequent being small bowel obstruction^[99]. However, most of these complications can be managed in a conservative manner and they usually do not require repeated surgical interventions.

In recent years there has been a renewed interest in treating refractory OD patients by a new surgical approach, designated as stapled transanal rectal resection^[100,101], conceived for correcting rectal intussusceptions and large rectoceles (usually at least 5 cm in diameter). Although this procedure may confer benefits to some patients over the short-term period, its efficacy is not superior to that achievable with osmotic laxatives^[102], it is burdened by several complications (*e.g.*, pain, bleeding, bowel perforation, fistulas, pelvic sepsis, peritonitis)^[103,104] and the results over the long-term period appear to be disappointing even in "ideal" patients^[105].

The interesting (although collateral) aspect of surgical procedures is the availability of full-thickness colonic or rectal tissue specimens, which are very useful for pathological investigations^[106,107]. Indeed, morphological analyses have the potential of disclosing useful information for understanding the pathophysiological bases of severe constipation^[108,109].

Another approach that can be attempted in patients with refractory constipation deals with sacral nerve stimulation (or sacral neuromodulation). This technique is based on the physiological principle that the presence of bioelectrical activity in one neural pathway can modulate a pre-existing activity in another pathway through synaptic interactions. It is carried out by percutaneous placement of an electrode in the third sacral foramen and implantation of a stimulating device under the skin in the buttocks^[110]. Although it may be effective in individual patients, the overall efficacy of sacral nerve stimulation is limited and unpredictable^[111], with positive results reported in 40%-100% of cases^[112]. Therefore, it requires additional well conducted prospective studies to assess its exact role and safety in the management of constipated patients as there is a significant underreporting of the incidence of untoward events associated with this technique^[113].

CONCLUSION

To date, the refractoriness of constipation to medical treatments is still a significant issue. Current literature on this topic suggests that a number of pharmacological or non-pharmacological therapeutic options can be offered to patients with true constipation refractory to first-line conventional treatments. However, for the majority of such options, the available supportive evidence is scanty and the clinical outcomes are often not satisfactory. A number of different factors are likely to contribute to these deficiencies, particularly: anecdotal or heterogeneous findings in a limited number of patients; data stemming from randomized clinical trials which may not meet the needs of real clinical life and are usually not suitable for designing tailored interventions based on the pathophysiology of individual patients; and scarcity or lack of information on the possible efficacy and, most importantly, safety of long-term treatments. Besides these arguments, both the literature and daily clinical practice clearly point out that, in a proportion of patients, the refractoriness of their constipation cannot be overcome even with second-line pharmacological interventions and that these subjects become candidates for third-line, more aggressive and/or demolitive, non-pharmacological/surgical therapeutic options which do not ensure favorable outcomes while posing relevant safety issues. Urgent and intensive clinical research efforts are therefore needed to address and resolve these problems. Besides attempts of identifying and developing novel drugs endowed with innovative mechanisms of actions, consistent efforts should be focused on the implementation of improved treatment regimens based on currently available old and

new drugs to pursue optimized benefit/risk ratios and long-term maintenance of constipation relief. In this context, attention should be paid to drug combination and/or alternating administration regimens which, while taking advantage of different mechanisms of action, would prevent excessive dose increments of the individual drugs and/or the loss of therapeutic effectiveness on long-term exposure as a possible consequence of tolerance. In particular, based on preliminary evidence and experience in daily clinical practice, combinations of enterokinetics with laxatives (either osmotic or stimulant), enterokinetics with secretagogues, different secretagogues, and even non-pharmacological interventions with enterokinetics or secretagogues might be worthy of validation by clinical research and subsequent consensus agreement by expert panels.

REFERENCES

- 1 **Bassotti G.** Understanding constipation treatment: do we need to strain to obtain better results? *Expert Opin Drug Metab Toxicol* 2013; **9**: 387-389 [PMID: 23419052 DOI: 10.1517/17425255.2013.773974]
- 2 **Gaburri M, Bassotti G, Bacci G, Cinti A, Bosso R, Ceccarelli P, Paolocci N, Pelli MA, Morelli A.** Functional gut disorders and health care seeking behavior in an Italian non-patient population. *Recenti Prog Med* 1989; **80**: 241-244 [PMID: 2762661]
- 3 **Choung RS, Shah ND, Chitkara D, Branda ME, Van Tilburg MA, Whitehead WE, Katusic SK, Locke GR, Talley NJ.** Direct medical costs of constipation from childhood to early adulthood: a population-based birth cohort study. *J Pediatr Gastroenterol Nutr* 2011; **52**: 47-54 [PMID: 20890220 DOI: 10.1097/MPG.0b013e3181e67058]
- 4 **Sanchez MI, Bercik P.** Epidemiology and burden of chronic constipation. *Can J Gastroenterol* 2011; **25** Suppl B: 11B-15B [PMID: 22114752]
- 5 **Choung RS, Branda ME, Chitkara D, Shah ND, Katusic SK, Locke GR, Talley NJ.** Longitudinal direct medical costs associated with constipation in women. *Aliment Pharmacol Ther* 2011; **33**: 251-260 [PMID: 21091523 DOI: 10.1111/j.1365-2036.2010.04513.x]
- 6 **Bharucha AE, Pemberton JH, Locke GR.** American Gastroenterological Association technical review on constipation. *Gastroenterology* 2013; **144**: 218-238 [PMID: 23261065 DOI: 10.1053/j.gastro.2012.10.028]
- 7 **Bassotti G, Villanacci V.** A practical approach to diagnosis and management of functional constipation in adults. *Intern Emerg Med* 2013; **8**: 275-282 [PMID: 21964837 DOI: 10.1007/s11739-011-0698-0]
- 8 **Wofford SA, Verne GN.** Approach to patients with refractory constipation. *Curr Gastroenterol Rep* 2000; **2**: 389-394 [PMID: 10998666 DOI: 10.1007/s11894-000-0038-4]
- 9 **Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC.** Functional bowel disorders. *Gastroenterology* 2006; **130**: 1480-1491 [PMID: 16678561 DOI: 10.1053/j.gastro.2005.11.061]
- 10 **Bharucha AE, Wald AM.** Anorectal disorders. *Am J Gastroenterol* 2010; **105**: 786-794 [PMID: 20372131 DOI: 10.1038/ajg.2010.70]
- 11 **Lee-Robichaud H, Thomas K, Morgan J, Nelson RL.** Lactulose versus Polyethylene Glycol for Chronic Constipation. *Cochrane Database Syst Rev* 2010; (7): CD007570 [PMID: 20614462]
- 12 **Müller-Lissner SA, Kamm MA, Scarpignato C, Wald A.** Myths and misconceptions about chronic constipation. *Am J Gastroenterol* 2005; **100**: 232-242 [PMID: 15654804 DOI: 10.1111/j.1572-0241.2005.40885.x]

- 13 **Diego L**, Atayee R, Helmons P, Hsiao G, von Gunten CF. Novel opioid antagonists for opioid-induced bowel dysfunction. *Expert Opin Investig Drugs* 2011; **20**: 1047-1056 [PMID: 21663526 DOI: 10.1517/13543784.2011.592830]
- 14 **Leroi AM**, Lalaude O, Antonietti M, Touchais JY, Ducrotte P, Menard JF, Denis P. Prolonged stationary colonic motility recording in seven patients with severe constipation secondary to antidepressants. *Neurogastroenterol Motil* 2000; **12**: 149-154 [PMID: 10771496 DOI: 10.1046/j.1365-2982.2000.00189.x]
- 15 **Bassotti G**. Motions and emotions: the treatment of depression causes constipation. *Neurogastroenterol Motil* 2000; **12**: 113-115 [PMID: 10771493 DOI: 10.1046/j.1365-2982.2000.00193.x]
- 16 **Solé LI**, Bolino MC, Lueso M, Caro L, Cerisoli C, Castiglia N, Bassotti G. Prevalence of sexual and physical abuse in patients with obstructed defecation: impact on biofeedback treatment. *Rev Esp Enferm Dig* 2009; **101**: 464-467 [PMID: 19642837 DOI: 10.4321/S1130-01082009000700003]
- 17 **Bove A**, Pucciani F, Bellini M, Battaglia E, Bocchini R, Altomare DF, Dodi G, Sciaudone G, Falletto E, Piloni V, Gambaccini D, Bove V. Consensus statement AIGO/SICCR: diagnosis and treatment of chronic constipation and obstructed defecation (part I: diagnosis). *World J Gastroenterol* 2012; **18**: 1555-1564 [PMID: 22529683 DOI: 10.3748/wjg.v18.i14.1555]
- 18 **Chaussade S**, Roche H, Khyari A, Couturier D, Guerre J. Measurement of colonic transit time: description and validation of a new method. *Gastroenterol Clin Biol* 1986; **10**: 385-389 [PMID: 3732742]
- 19 **Bassotti G**, Maggio D, Battaglia E, Giulietti O, Spinozzi F, Reboldi G, Serra AM, Emanuelli G, Chiarioni G. Manometric investigation of anorectal function in early and late stage Parkinson's disease. *J Neurol Neurosurg Psychiatry* 2000; **68**: 768-770 [PMID: 10811703 DOI: 10.1136/jnnp.68.6.768]
- 20 **Minguez M**, Herreros B, Sanchiz V, Hernandez V, Almela P, Añon R, Mora F, Benages A. Predictive value of the balloon expulsion test for excluding the diagnosis of pelvic floor dyssynergia in constipation. *Gastroenterology* 2004; **126**: 57-62 [PMID: 14699488 DOI: 10.1053/j.gastro.2003.10.044]
- 21 **Kim AY**. How to interpret a functional or motility test - defecography. *J Neurogastroenterol Motil* 2011; **17**: 416-420 [PMID: 22148112 DOI: 10.5056/jnm.2011.17.4.416]
- 22 **Bassotti G**, Stanghellini V, Chiarioni G, Germani U, De Giorgio R, Vantini I, Morelli A, Corinaldesi R. Upper gastrointestinal motor activity in patients with slow-transit constipation. Further evidence for an enteric neuropathy. *Dig Dis Sci* 1996; **41**: 1999-2005 [PMID: 8888714 DOI: 10.1007/BF02093603]
- 23 **De Giorgio R**, Barbara G, Stanghellini V, De Ponti F, Salvioli B, Tonini M, Velio P, Bassotti G, Corinaldesi R. Clinical and morphofunctional features of idiopathic myenteric ganglionitis underlying severe intestinal motor dysfunction: a study of three cases. *Am J Gastroenterol* 2002; **97**: 2454-2459 [PMID: 12358272 DOI: 10.1016/S0002-9270(02)04359-9]
- 24 **Bassotti G**, Gaburri M, Imbimbo BP, Rossi L, Farroni F, Pelli MA, Morelli A. Colonic mass movements in idiopathic chronic constipation. *Gut* 1988; **29**: 1173-1179 [PMID: 3197990 DOI: 10.1136/gut.29.9.1173]
- 25 **Bassotti G**, Betti C, Pelli MA, Morelli A. Extensive investigation on colonic motility with pharmacological testing is useful for selecting surgical options in patients with inertia colica. *Am J Gastroenterol* 1992; **87**: 143-147 [PMID: 1728113]
- 26 **Frattini JC**, Noguerras JJ. Slow transit constipation: a review of a colonic functional disorder. *Clin Colon Rectal Surg* 2008; **21**: 146-152 [PMID: 20011411 DOI: 10.1055/s-2008-1075864]
- 27 **Bassotti G**, Roberto GD, Sediari L, Morelli A. Toward a definition of colonic inertia. *World J Gastroenterol* 2004; **10**: 2465-2467 [PMID: 15300885]
- 28 **Rao SS**, Welcher KD, Leistikow JS. Obstructive defecation: a failure of rectoanal coordination. *Am J Gastroenterol* 1998; **93**: 1042-1050 [PMID: 9672327 DOI: 10.1111/j.1572-0241.1998.00326.x]
- 29 **Faucheron JL**, Dubreuil A. Rectal akinesia as a new cause of impaired defecation. *Dis Colon Rectum* 2000; **43**: 1545-1549 [PMID: 11089590 DOI: 10.1007/BF02236736]
- 30 **Karlbom U**, Lundin E, Graf W, Pählman L. Anorectal physiology in relation to clinical subgroups of patients with severe constipation. *Colorectal Dis* 2004; **6**: 343-349 [PMID: 15335368 DOI: 10.1111/j.1463-1318.2004.00632.x]
- 31 **Khaikin M**, Wexner SD. Treatment strategies in obstructed defecation and fecal incontinence. *World J Gastroenterol* 2006; **12**: 3168-3173 [PMID: 16718835]
- 32 **Bassotti G**, Chiarioni G, Germani U, Battaglia E, Vantini I, Morelli A. Endoluminal instillation of bisacodyl in patients with severe (slow transit type) constipation is useful to test residual colonic propulsive activity. *Digestion* 1999; **60**: 69-73 [PMID: 9892801 DOI: 10.1159/00007591]
- 33 **Kienzle-Horn S**, Vix JM, Schuijt C, Peil H, Jordan CC, Kamm MA. Efficacy and safety of bisacodyl in the acute treatment of constipation: a double-blind, randomized, placebo-controlled study. *Aliment Pharmacol Ther* 2006; **23**: 1479-1488 [PMID: 16669963 DOI: 10.1111/j.1365-2036.2006.02903.x]
- 34 **Kienzle-Horn S**, Vix JM, Schuijt C, Peil H, Jordan CC, Kamm MA. Comparison of bisacodyl and sodium picosulphate in the treatment of chronic constipation. *Curr Med Res Opin* 2007; **23**: 691-699 [PMID: 17407625 DOI: 10.1185/030079907X178865]
- 35 **Mueller-Lissner S**, Kamm MA, Wald A, Hinkel U, Koehler U, Richter E, Bubeck J. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. *Am J Gastroenterol* 2010; **105**: 897-903 [PMID: 20179697 DOI: 10.1038/ajg.2010.41]
- 36 **Kamm MA**, Mueller-Lissner S, Wald A, Richter E, Swallow R, Gessner U. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. *Clin Gastroenterol Hepatol* 2011; **9**: 577-583 [PMID: 21440672 DOI: 10.1016/j.cgh.2011.03.026]
- 37 **Villanacci V**, Bassotti G, Cathomas G, Maurer CA, Di Fabio F, Fisogni S, Cadei M, Mazzocchi A, Salerni B. Is pseudomelanosis coli a marker of colonic neuropathy in severely constipated patients? *Histopathology* 2006; **49**: 132-137 [PMID: 16879390 DOI: 10.1111/j.1365-2559.2006.02481.x]
- 38 **Liu LW**. Chronic constipation: current treatment options. *Can J Gastroenterol* 2011; **25** Suppl B: 22B-28B [PMID: 22114754]
- 39 **Bassotti G**, Villanacci V. Motility: prucalopride for chronic constipation. *Nat Rev Gastroenterol Hepatol* 2009; **6**: 324-325 [PMID: 19494821 DOI: 10.1038/nrgastro.2009.81]
- 40 **Frampton JE**. Prucalopride. *Drugs* 2009; **69**: 2463-2476 [PMID: 19911858 DOI: 10.2165/11204000-000000000-00000]
- 41 **Bouras EP**, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. *Gastroenterology* 2001; **120**: 354-360 [PMID: 11159875 DOI: 10.1053/gast.2001.21166]
- 42 **De Schryver AM**, Andriessse GI, Samsom M, Smout AJ, Gooszen HG, Akkermans LM. The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. *Aliment Pharmacol Ther* 2002; **16**: 603-612 [PMID: 11876716 DOI: 10.1046/j.1365-2036.2002.01195.x]
- 43 **Camilleri M**, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. *N Engl J Med* 2008; **358**: 2344-2354 [PMID: 18509121 DOI: 10.1056/NEJMoa0800670]
- 44 **Quigley EM**, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study. *Aliment Pharmacol Ther* 2009; **29**: 315-328 [PMID: 19035970 DOI: 10.1111/j.1365-2036.2008.03884.x]
- 45 **Camilleri M**, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study.

- Neurogastroenterol Motil* 2009; **21**: 1256-e117 [PMID: 19751247 DOI: 10.1111/j.1365-2982.2009.01398.x]
- 46 **Müller-Lissner S**, Rykx A, Kerstens R, Vandeplassche L. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. *Neurogastroenterol Motil* 2010; **22**: 991-998, e255 [PMID: 20529205 DOI: 10.1111/j.1365-2982.2010.01533.x]
- 47 **Camilleri M**, Van Outryve MJ, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies. *Aliment Pharmacol Ther* 2010; **32**: 1113-1123 [PMID: 21039673 DOI: 10.1111/j.1365-2036.2010.04455.x]
- 48 **Ke M**, Zou D, Yuan Y, Li Y, Lin L, Hao J, Hou X, Kim HJ. Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. *Neurogastroenterol Motil* 2012; **24**: 999-e541 [PMID: 22882724 DOI: 10.1111/j.1365-2982.2012.01983.x]
- 49 **Tack J**, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. *Gut* 2009; **58**: 357-365 [PMID: 18987031 DOI: 10.1136/gut.2008.162404]
- 50 **Jadav AM**, McMullin CM, Smith J, Chapple K, Brown SR. The association between prucalopride efficacy and constipation type. *Tech Coloproctol* 2013; **17**: 555-559 [PMID: 23703575 DOI: 10.1007/s10151-013-1017-8]
- 51 **Bassotti G**, Bellini M. The use of prucalopride in real life for the treatment of constipation subtypes: ups and downs. *Tech Coloproctol* 2013; **17**: 475-476 [PMID: 23703576 DOI: 10.1007/s10151-013-1026-7]
- 52 **Cinca R**, Chera D, Gruss HJ, Halphen M. Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation -- a comparison in a controlled environment. *Aliment Pharmacol Ther* 2013; **37**: 876-886 [PMID: 23480216 DOI: 10.1111/apt.12278]
- 53 **Lacy BE**, Chey WD. Lubiprostone: chronic constipation and irritable bowel syndrome with constipation. *Expert Opin Pharmacother* 2009; **10**: 143-152 [PMID: 19236188 DOI: 10.1517/14656560802631319]
- 54 **Johanson JF**, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. *Aliment Pharmacol Ther* 2007; **25**: 1351-1361 [PMID: 17509103 DOI: 10.1111/j.1365-2036.2007.03320.x]
- 55 **Johanson JF**, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. *Am J Gastroenterol* 2008; **103**: 170-177 [PMID: 17916109 DOI: 10.1111/j.1572-0241.2007.01524.x]
- 56 **Barish CF**, Drossman D, Johanson JF, Ueno R. Efficacy and safety of lubiprostone in patients with chronic constipation. *Dig Dis Sci* 2010; **55**: 1090-1097 [PMID: 20012484 DOI: 10.1007/s10620-009-1068-x]
- 57 **Fukudo S**, Hongo M, Kaneko H, Ueno R. Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study. *Neurogastroenterol Motil* 2011; **23**: 544-e205 [PMID: 21303430 DOI: 10.1111/j.1365-2982.2011.01668.x]
- 58 **Leambo AJ**, Johanson JF, Parkman HP, Rao SS, Miner PB, Ueno R. Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. *Dig Dis Sci* 2011; **56**: 2639-2645 [PMID: 21769655 DOI: 10.1007/s10620-011-1801-0]
- 59 **Busby RW**, Kessler MM, Bartolini WP, Bryant AP, Hannig G, Higgins CS, Solinga RM, Tobin JV, Wakefield JD, Kurtz CB, Currie MG. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. *J Pharmacol Exp Ther* 2013; **344**: 196-206 [PMID: 23090647 DOI: 10.1124/jpet.112.199430]
- 60 **Johnston JM**, Kurtz CB, Drossman DA, Lembo AJ, Jeglinski BI, MacDougall JE, Antonelli SM, Currie MG. Pilot study on the effect of linaclotide in patients with chronic constipation. *Am J Gastroenterol* 2009; **104**: 125-132 [PMID: 19098860 DOI: 10.1038/ajg.2008.59]
- 61 **Leambo AJ**, Kurtz CB, MacDougall JE, Lavins BJ, Currie MG, Fitch DA, Jeglinski BI, Johnston JM. Efficacy of linaclotide for patients with chronic constipation. *Gastroenterology* 2010; **138**: 886-95.e1 [PMID: 20045700 DOI: 10.1053/j.gastro.2009.12.050]
- 62 **Leambo AJ**, Schneier HA, Shiff SJ, Kurtz CB, MacDougall JE, Jia XD, Shao JZ, Lavins BJ, Currie MG, Fitch DA, Jeglinski BI, Eng P, Fox SM, Johnston JM. Two randomized trials of linaclotide for chronic constipation. *N Engl J Med* 2011; **365**: 527-536 [PMID: 21830967 DOI: 10.1056/NEJMoa1010863]
- 63 **Videllock EJ**, Cheng V, Cremonini F. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis. *Clin Gastroenterol Hepatol* 2013; **11**: 1084-1092.e3; quiz e68 [PMID: 23644388 DOI: 10.1016/j.cgh.2013.04.032]
- 64 **Verne GN**, Eaker EY, Davis RH, Sninsky CA. Colchicine is an effective treatment for patients with chronic constipation: an open-label trial. *Dig Dis Sci* 1997; **42**: 1959-1963 [PMID: 9331162]
- 65 **Verne GN**, Davis RH, Robinson ME, Gordon JM, Eaker EY, Sninsky CA. Treatment of chronic constipation with colchicine: randomized, double-blind, placebo-controlled, crossover trial. *Am J Gastroenterol* 2003; **98**: 1112-1116 [PMID: 12809836]
- 66 **Taghavi SA**, Shabani S, Mehrmiri A, Eshraghian A, Kazemi SM, Moeini M, Hosseini-Asl SM, Saberifirooz M, Alizade-Naeni M, Mostaghni AA. Colchicine is effective for short-term treatment of slow transit constipation: a double-blind placebo-controlled clinical trial. *Int J Colorectal Dis* 2010; **25**: 389-394 [PMID: 19705134 DOI: 10.1007/s00384-009-0794-z]
- 67 **Roubille F**, Kritikou E, Busseuil D, Barrere-Lemaire S, Tardif JC. Colchicine: an old wine in a new bottle? *Antiinflamm Antiallergy Agents Med Chem* 2013; **12**: 14-23 [PMID: 23286287 DOI: 10.2174/1871523011312010004]
- 68 **Simrén M**, Bajor A, Gillberg PG, Rudling M, Abrahamsson H. Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation--a double-blind study. *Aliment Pharmacol Ther* 2011; **34**: 41-50 [PMID: 21545606 DOI: 10.1111/j.1365-2036.2011.04675.x]
- 69 **Wong BS**, Camilleri M, McKinzie S, Burton D, Graffner H, Zinsmeister AR. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. *Am J Gastroenterol* 2011; **106**: 2154-2164 [PMID: 21876564 DOI: 10.1038/ajg.2011.285]
- 70 **Chey WD**, Camilleri M, Chang L, Rikner L, Graffner H. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. *Am J Gastroenterol* 2011; **106**: 1803-1812 [PMID: 21606974 DOI: 10.1038/ajg.2011.162]
- 71 **Bharucha AE**, Low P, Camilleri M, Veil E, Burton D, Kudva Y, Shah P, Gehrking T, Zinsmeister AR. A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation. *Gut* 2013; **62**: 708-715 [PMID: 22677718 DOI: 10.1136/gutjnl-2012-302483]
- 72 **Bassotti G**, Whitehead WE. Biofeedback as a treatment approach to gastrointestinal tract disorders. *Am J Gastroenterol* 1994; **89**: 158-164 [PMID: 8304295]
- 73 **Bassotti G**, Whitehead WE. Biofeedback, relaxation training, and cognitive behaviour modification as treatments for lower functional gastrointestinal disorders. *QJM* 1997; **90**:

- 545-550 [PMID: 9327034 DOI: 10.1093/qjmed/90.8.545]
- 74 **Palsson OS**, Whitehead WE. Psychological treatments in functional gastrointestinal disorders: a primer for the gastroenterologist. *Clin Gastroenterol Hepatol* 2013; **11**: 208-16; quiz e22-23 [PMID: 23103907 DOI: 10.1016/j.cgh.2012.10.031]
- 75 **Bassotti G**, Chistolini F, Sietchiping-Nzepa F, de Roberto G, Morelli A, Chiarioni G. Biofeedback for pelvic floor dysfunction in constipation. *BMJ* 2004; **328**: 393-396 [PMID: 14962877 DOI: 10.1136/bmj.328.7436.393]
- 76 **Rao SS**. Biofeedback therapy for constipation in adults. *Best Pract Res Clin Gastroenterol* 2011; **25**: 159-166 [PMID: 21382587 DOI: 10.1016/j.bpg.2011.01.004]
- 77 **Battaglia E**, Serra AM, Buonafede G, Dughera L, Chistolini F, Morelli A, Emanuelli G, Bassotti G. Long-term study on the effects of visual biofeedback and muscle training as a therapeutic modality in pelvic floor dyssynergia and slow-transit constipation. *Dis Colon Rectum* 2004; **47**: 90-95 [PMID: 14702645 DOI: 10.1007/s10350-003-0010-0]
- 78 **Chiarioni G**, Whitehead WE, Pezza V, Morelli A, Bassotti G. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. *Gastroenterology* 2006; **130**: 657-664 [PMID: 16530506 DOI: 10.1053/j.gastro.2005.11.014]
- 79 **Heymen S**, Scarlett Y, Jones K, Ringel Y, Drossman D, Whitehead WE. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. *Dis Colon Rectum* 2007; **50**: 428-441 [PMID: 17294322 DOI: 10.1007/s10350-006-0814-9]
- 80 **Rao SS**, Seaton K, Miller M, Brown K, Nygaard I, Stumbo P, Zimmerman B, Schulze K. Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. *Clin Gastroenterol Hepatol* 2007; **5**: 331-338 [PMID: 17368232 DOI: 10.1016/j.cgh.2006.12.023]
- 81 **Rao SS**, Valestin J, Brown CK, Zimmerman B, Schulze K. Long-term efficacy of biofeedback therapy for dyssynergic defecation: randomized controlled trial. *Am J Gastroenterol* 2010; **105**: 890-896 [PMID: 20179692 DOI: 10.1038/ajg.2010.53]
- 82 **Pourmomeny AA**, Emami MH, Amooshahi M, Adibi P. Comparing the efficacy of biofeedback and balloon-assisted training in the treatment of dyssynergic defecation. *Can J Gastroenterol* 2011; **25**: 89-92 [PMID: 21321680]
- 83 **Hart SL**, Lee JW, Berian J, Patterson TR, Del Rosario A, Varma MG. A randomized controlled trial of anorectal biofeedback for constipation. *Int J Colorectal Dis* 2012; **27**: 459-466 [PMID: 22159695 DOI: 10.1007/s00384-011-1355-9]
- 84 **Simón MA**, Bueno AM. Behavioural treatment of the dys-synergic defecation in chronically constipated elderly patients: a randomized controlled trial. *Appl Psychophysiol Biofeedback* 2009; **34**: 273-277 [PMID: 19618262 DOI: 10.1007/s10484-009-9100-7]
- 85 **Farid M**, El Monem HA, Omar W, El Nakeeb A, Fikry A, Youssef T, Yousef M, Ghazy H, Fouda E, El Metwally T, Khafagy W, Ahmed S, El Awady S, Morshed M, El Lithy R. Comparative study between biofeedback retraining and botulinum neurotoxin in the treatment of anismus patients. *Int J Colorectal Dis* 2009; **24**: 115-120 [PMID: 18719924 DOI: 10.1007/s00384-008-0567-0]
- 86 **Enck P**, Van der Voort IR, Klosterhalfen S. Biofeedback therapy in fecal incontinence and constipation. *Neurogastroenterol Motil* 2009; **21**: 1133-1141 [PMID: 19566591 DOI: 10.1111/j.1365-2982.2009.01345.x]
- 87 **Chiarioni G**, Chistolini F, Menegotti M, Salandini L, Vantini I, Morelli A, Bassotti G. One-year follow-up study on the effects of electrogalvanic stimulation in chronic idiopathic constipation with pelvic floor dyssynergia. *Dis Colon Rectum* 2004; **47**: 346-353 [PMID: 14991497 DOI: 10.1007/s10350-003-0047-1]
- 88 **Starr JA**, Drobnis EZ, Lengler S, Parrot J, Barrier B, Foster R. Outcomes of a comprehensive nonsurgical approach to pelvic floor rehabilitation for urinary symptoms, defecatory dysfunction, and pelvic pain. *Female Pelvic Med Reconstr Surg* 2013; **19**: 260-265 [PMID: 23982573 DOI: 10.1097/SPV.0b013e31829cbb9b]
- 89 **Maria G**, Cadeddu F, Brandara F, Marniga G, Brisinda G. Experience with type A botulinum toxin for treatment of outlet-type constipation. *Am J Gastroenterol* 2006; **101**: 2570-2575 [PMID: 17029615 DOI: 10.1111/j.1572-0241.2006.00791.x]
- 90 **Faried M**, El Nakeeb A, Youssef M, Omar W, El Monem HA. Comparative study between surgical and non-surgical treatment of anismus in patients with symptoms of obstructed defecation: a prospective randomized study. *J Gastrointest Surg* 2010; **14**: 1235-1243 [PMID: 20499203 DOI: 10.1007/s11605-010-1229-4]
- 91 **Siddiqui AA**, Fishman SJ, Bauer SB, Nurko S. Long-term follow-up of patients after antegrade continence enema procedure. *J Pediatr Gastroenterol Nutr* 2011; **52**: 574-580 [PMID: 21502828 DOI: 10.1097/MPG.0b013e3181ff6042]
- 92 **Worsøe J**, Christensen P, Krogh K, Buntzen S, Laurberg S. Long-term results of antegrade colonic enema in adult patients: assessment of functional results. *Dis Colon Rectum* 2008; **51**: 1523-1528 [PMID: 18622642 DOI: 10.1007/s10350-008-9401-6]
- 93 **Meurette G**, Lehur PA, Coron E, Regenet N. Long-term results of Malone's procedure with antegrade irrigation for severe chronic constipation. *Gastroenterol Clin Biol* 2010; **34**: 209-212 [PMID: 20299171 DOI: 10.1016/j.gcb.2009.12.009]
- 94 **Wexner SD**, Daniel N, Jagelman DG. Colectomy for constipation: physiologic investigation is the key to success. *Dis Colon Rectum* 1991; **34**: 851-856 [PMID: 1914716 DOI: 10.1007/BF02049695]
- 95 **Redmond JM**, Smith GW, Barofsky I, Ratych RE, Goldsborough DC, Schuster MM. Physiological tests to predict long-term outcome of total abdominal colectomy for intractable constipation. *Am J Gastroenterol* 1995; **90**: 748-753 [PMID: 7733081]
- 96 **Sohn G**, Yu CS, Kim CW, Kwak JY, Jang TY, Kim KH, Yang SS, Yoon YS, Lim SB, Kim JC. Surgical outcomes after total colectomy with ileorectal anastomosis in patients with medically intractable slow transit constipation. *J Korean Soc Coloproctol* 2011; **27**: 180-187 [PMID: 21980588 DOI: 10.3393/jksc.2011.27.4.180]
- 97 **Hassan I**, Pemberton JH, Young-Fadok TM, You YN, Drelichman ER, Rath-Harvey D, Schleck CD, Larson DR. Ileorectal anastomosis for slow transit constipation: long-term functional and quality of life results. *J Gastrointest Surg* 2006; **10**: 1330-1336; discussion 1330-1336; [PMID: 17175451 DOI: 10.1016/j.gassur.2006.09.006]
- 98 **Kamm MA**, Hawley PR, Lennard-Jones JE. Outcome of colectomy for severe idiopathic constipation. *Gut* 1988; **29**: 969-973 [PMID: 3396968 DOI: 10.1136/gut.29.7.969]
- 99 **Nyam DC**, Pemberton JH, Ilstrup DM, Rath DM. Long-term results of surgery for chronic constipation. *Dis Colon Rectum* 1997; **40**: 273-279 [PMID: 9118740 DOI: 10.1007/BF02050415]
- 100 **Harris MA**, Ferrara A, Gallagher J, DeJesus S, Williamson P, Larach S. Stapled transanal rectal resection vs. transvaginal rectocele repair for treatment of obstructive defecation syndrome. *Dis Colon Rectum* 2009; **52**: 592-597 [PMID: 19404059 DOI: 10.1007/DCR.0b013e31819eddb1]
- 101 **Levitt MA**, Mathis KL, Pemberton JH. Surgical treatment for constipation in children and adults. *Best Pract Res Clin Gastroenterol* 2011; **25**: 167-179 [PMID: 21382588 DOI: 10.1016/j.bpg.2010.12.007]
- 102 **Biviano I**, Badiali D, Candeloro L, Habib FI, Mongardini M, Caviglia A, Anzini F, Corazziari ES. Comparative outcome of stapled trans-anal rectal resection and macrogol in the treatment of defecation disorders. *World J Gastroenterol* 2011; **17**: 4199-4205 [PMID: 22072851 DOI: 10.3748/wjg.v17.i37.4199]

- 103 **Dodi G**, Pietroletti R, Milito G, Binda G, Pescatori M. Bleeding, incontinence, pain and constipation after STARR transanal double stapling rectotomy for obstructed defecation. *Tech Coloproctol* 2003; **7**: 148-153 [PMID: 14628157 DOI: 10.1007/s10151-003-0026-4]
- 104 **Schwandner O**, Fürst A. Assessing the safety, effectiveness, and quality of life after the STARR procedure for obstructed defecation: results of the German STARR registry. *Langenbecks Arch Surg* 2010; **395**: 505-513 [PMID: 20549229 DOI: 10.1007/s00423-009-0591-8]
- 105 **Madbouly KM**, Abbas KS, Hussein AM. Disappointing long-term outcomes after stapled transanal rectal resection for obstructed defecation. *World J Surg* 2010; **34**: 2191-2196 [PMID: 20533038 DOI: 10.1007/s00268-010-0638-6]
- 106 **Bassotti G**, Villanacci V, Salerni B, Maurer CA, Cathomas G. Beyond hematoxylin and eosin: the importance of immunohistochemical techniques for evaluating surgically resected constipated patients. *Tech Coloproctol* 2011; **15**: 371-375 [PMID: 21766200 DOI: 10.1007/s10151-011-0721-5]
- 107 **Bernardini N**, Ippolito C, Segnani C, Mattii L, Bassotti G, Villanacci V, Blandizzi C, Dolfi A. Histopathology in gastrointestinal neuromuscular diseases: methodological and ontological issues. *Adv Anat Pathol* 2013; **20**: 17-31 [PMID: 23232568 DOI: 10.1097/PAP.0b013e31827b65c0]
- 108 **Bassotti G**, Villanacci V, Maurer CA, Fisogni S, Di Fabio F, Cadei M, Morelli A, Panagiotis T, Cathomas G, Salerni B. The role of glial cells and apoptosis of enteric neurones in the neuropathology of intractable slow transit constipation. *Gut* 2006; **55**: 41-46 [PMID: 16041063 DOI: 10.1136/gut.2005.073197]
- 109 **Bassotti G**, Villanacci V, Bellomi A, Fante R, Cadei M, Vicenzi L, Tonelli F, Nesi G, Asteria CR. An assessment of enteric nervous system and estroprogestinic receptors in obstructed defecation associated with rectal intussusception. *Neurogastroenterol Motil* 2012; **24**: e155-e161 [PMID: 22188470 DOI: 10.1111/j.1365-2982.2011.01850.x]
- 110 **van Wunnik BP**, Baeten CG, Southwell BR. Neuromodulation for constipation: sacral and transcutaneous stimulation. *Best Pract Res Clin Gastroenterol* 2011; **25**: 181-191 [PMID: 21382589 DOI: 10.1016/j.bpg.2010.12.008]
- 111 **Ortiz H**, de Miguel M, Rinaldi M, Oteiza F, Altomare DF. Functional outcome of sacral nerve stimulation in patients with severe constipation. *Dis Colon Rectum* 2012; **55**: 876-880 [PMID: 22810473 DOI: 10.1097/DCR.0b013e31825bc9af]
- 112 **Thomas GP**, Dudding TC, Rahbour G, Nicholls RJ, Vaizey CJ. Sacral nerve stimulation for constipation. *Br J Surg* 2013; **100**: 174-181 [PMID: 23124687 DOI: 10.1002/bjs.8944]
- 113 **Maeda Y**, Matzel K, Lundby L, Buntzen S, Laurberg S. Post-operative issues of sacral nerve stimulation for fecal incontinence and constipation: a systematic literature review and treatment guideline. *Dis Colon Rectum* 2011; **54**: 1443-1460 [PMID: 21979192 DOI: 10.1097/DCR.0b013e318227f65d]

P- Reviewers: Kristina L, Kumar A, Liu S **S- Editor:** Zhai HH
L- Editor: Roemmele A **E- Editor:** Wu HL





百世登

Baishideng®

Published by **Baishideng Publishing Group Co., Limited**

Flat C, 23/F., Lucky Plaza,

315-321 Lockhart Road, Wan Chai, Hong Kong, China

Fax: +852-65557188

Telephone: +852-31779906

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

